- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04543669
Adacel® Booster Vaccination for CMI Assay Development
Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development
Recruitment of individuals primed during childhood with TdaP (tetanus, diphtheria , acellular pertussis) vaccine, and administration of an Adacel booster with blood sample collection at various time points before and after vaccination.
Collection of blood sample volumes will be large enough to allow assessment and comparison of multiple assays that evaluate cell-mediated immune (CMI) responses and other biomarkers following the administration of pertussis vaccinations. The ultimate objective would be to utilize these validated assays for evaluation of pertussis clinical trial results or development of new pertussis vaccine formulations.
Study Overview
Detailed Description
Pertussis, known as "whooping cough", is caused by the bacterium Bordetella pertussis which was discovered over a century ago. Human vaccines were developed in the subsequent two decades and routine childhood immunization has been practiced for over 60 years. Yet, B. pertussis remains a significant cause of morbidity in children and adults worldwide. Globally, about 20-40 million cases of pertussis are reported each year, with about 400,000 cases being fatal. The incidence of pertussis is highest and the severity the greatest in children under 6 months of age. Vaccination and natural infection are not protective for life, and the reason is unclear. The epidemiologic features of B. pertussis infections in older individuals who are only partially immune from prior infections and immunizations are not well understood. Clarification is important, in light of studies that suggest that pertussis is a cause of prolonged cough illness in adults who serve as the reservoir of B. pertussis and are the major source of infection for infants in whom the disease has substantial morbidity and mortality. With the considerable increase in cases and outbreaks, there is an imminent need for improved immunogenic and efficacious pertussis vaccines, paired with the best tools to evaluate vaccines and vaccine programs.
VaxDesign has proposed two studies for acellular vaccine primed (acP) versus whole cell vaccine primed (wcP) donors, to further develop and validate a number of practical assays for use as biomarkers and to define a baseline readout for pertussis vaccinations from these two cohorts. In addition, these assays will be optimized to use the small blood volumes that are routinely available from clinical studies. In contrast to measuring humoral immune responses, the cell mediated immune response (CMI) is a substantially more challenging parameter to assess and thus the sample volumes required for the study must be large enough to allow the multiple different assessments. In this study, samples will be taken to evaluate transcriptomics, and humoral and cellular immunity over a one month period following vaccination. The collaboration with the Canadian Center for Vaccinology (CCfV) offers a unique opportunity of easily accessing acellular vaccine primed individuals.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Canadian Center for Vaccinology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥16years
- Primed during infancy with an acellular pertussis vaccine
- Good general health status, as determined by history no greater than 30 days prior to administration of the first test article
- Written informed consent provided
- If female of child-bearing potential, has a negative pregnancy test on the day of consent and has agreed to continue adequate contraception until after the last blood draw.
Exclusion Criteria:
- Not primed in infancy with an acellular pertussis vaccine
- History of anemia
- Underlying chronic medical condition requiring ongoing monitoring by a physician (e.g., diabetes, seizure disorder)
- Underlying cardiac and/or pulmonary disease including hypertension, angina, prior myocardial infection, asthma, emphysema, chronic bronchitis, and pulmonary tuberculosis
- Pregnant (known before or established at the time of screening using a urine-based test)
- Immunocompromised (reporting HIV/AIDS positive or receiving immunosuppressive therapy involving steroids)
- Vaccinated against pertussis within previous 5 years
- Refusing to get an Adacel® (TdaP) vaccination dose
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Adacel®
All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
|
Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine best assay to evaluate CMI responses post-vaccination: CD4 T-cell proliferation
Time Frame: Days -14 to 28
|
% CD4+CTV-T cells analyzed by flow cytometry
|
Days -14 to 28
|
Determine best assay to evaluate CMI responses post-vaccination: CD8 T-cell proliferation
Time Frame: Days -14 to 28
|
% CD8+ CTV-T cells analyzed by flow cytometry
|
Days -14 to 28
|
Determine optimal time point for sample collection: CD4 T-cell responses
Time Frame: Days -14 to 28
|
% CD4+CTV-cytokine+T cells analyzed by flow cytometry
|
Days -14 to 28
|
Determine optimal time point for sample collection: CD8 T-cell responses
Time Frame: Days -14 to 28
|
% CD8+ CTV-cytokine+T cells analyzed by flow cytometry
|
Days -14 to 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transcriptomic profiling of host - B. pertussis antigen interactions: B-cell plasmablasts
Time Frame: Days -7, 7, 14, and 28
|
ASC per 106 PBMCs (ELISpot)
|
Days -7, 7, 14, and 28
|
Transcriptomic profiling of host - B. pertussis antigen interactions: B-cell plasmablasts
Time Frame: Days -7, 7, 14, and 28
|
% CD19+ CD38+ CD27+ cells
|
Days -7, 7, 14, and 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP1601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pertussis
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Pertussis ImmunisationUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis (Whooping Cough)France
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... and other collaboratorsNot yet recruitingBordetella Pertussis, Whooping CoughFrance
-
ILiAD BiotechnologiesActive, not recruitingBordetella Pertussis, Whooping CoughUnited Kingdom, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyCompleted
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...CompletedBordetella Pertussis, Whooping CoughCambodia, Madagascar, Togo
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
GlaxoSmithKlineCompletedPertussis | Pertussis VaccinesHungary
-
University of SouthamptonRecruitingPertussis/Whooping CoughUnited Kingdom
-
Association Clinique Thérapeutique Infantile du...Sanofi; GlaxoSmithKline; Merck Sharp & Dohme LLCRecruitingChildren, Only | Ambulatory | Pertussis/Whooping CoughFrance
Clinical Trials on Adacel®
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaCanada
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
SanofiCompletedPertussis | Tetanus | DiphtheriaUnited States
-
SanofiCompletedPertussis | Tetanus | DiphtheriaUnited States
-
SanofiCompletedPertussis | Tetanus | DiphtheriaUnited States
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular PertussisUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaJapan
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | Diphtheria | Meningitis | MeningococcemiaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaUnited States, Canada
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States